Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade

NCT03474497 is registered in ClinicalTrials.gov with Megan Daly, MD as lead sponsor.

NCT NCT03474497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade
Lead sponsor
Megan Daly, MD
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 20, 2019
Completion date
February 28, 2026
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, metastatic melanoma, metastatic renal cell carcinoma, non small cell lung cancer